-
公开(公告)号:US12016865B2
公开(公告)日:2024-06-25
申请号:US16229898
申请日:2018-12-21
申请人: Cormedix Inc.
发明人: Robert DiLuccio , Bruce Reidenberg
IPC分类号: A61K31/549 , A61K9/48 , A61K9/51 , A61K47/54 , A61P31/10
CPC分类号: A61K31/549 , A61K9/4833 , A61K9/4891 , A61K9/5161 , A61K47/555 , A61P31/10
摘要: A method for treating Candida auris in blood, comprising administering to the blood taurolidine, and/or one or more taurolidine derivatives, in a concentration which is effective to treat C. auris in the blood.
-
公开(公告)号:US20230390300A1
公开(公告)日:2023-12-07
申请号:US18091504
申请日:2022-12-30
申请人: CorMedix Inc.
发明人: Bruce Reidenberg , Robert DiLuccio
IPC分类号: A61K31/549 , A61K31/18 , A61K47/34 , A61K9/00 , A61K9/14 , A61K31/047
CPC分类号: A61K31/549 , A61K31/18 , A61K31/047 , A61K9/0019 , A61K9/14 , A61K47/34
摘要: Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically-resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. The efficacy in rodent model is superior to the efficacy in cell culture. This invention relates to the use of taurolidine hydrolysis products (tarultam and/or taurinamide and/or methylene glycol and/or selected combinations thereof) for the treatment of neuroblastoma in juvenile mammals.
-
公开(公告)号:US20170056333A1
公开(公告)日:2017-03-02
申请号:US15253176
申请日:2016-08-31
申请人: CorMedix Inc.
发明人: Robert DiLuccio , Randy Milby
IPC分类号: A61K9/70 , A61K47/34 , A61K31/549
CPC分类号: A61K31/549 , A61K9/70 , A61K47/34
摘要: An active agent delivery system comprising a nanofiber web and an active agent carried by the nanofiber web.
摘要翻译: 一种包含纳米纤维网和由纳米纤维网承载的活性剂的活性剂递送系统。
-
公开(公告)号:US20220323450A1
公开(公告)日:2022-10-13
申请号:US17530138
申请日:2021-11-18
申请人: CorMedix Inc.
发明人: Bruce Reidenberg , Robert DiLuccio
IPC分类号: A61K31/549 , A61K9/00 , A61K9/14
摘要: Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically-resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. This invention relates to the use of taurolidine for the treatment of neuroblastoma in juvenile mammals.
-
公开(公告)号:US20210085686A1
公开(公告)日:2021-03-25
申请号:US17063142
申请日:2020-10-05
申请人: CorMedix Inc.
发明人: Robert DiLuccio , Randy Milby
IPC分类号: A61K31/549 , A61K9/70
摘要: An active agent delivery system comprising a nanofiber web and an active agent carried by the nanofiber web.
-
6.
公开(公告)号:US20180207103A1
公开(公告)日:2018-07-26
申请号:US15928988
申请日:2018-03-22
申请人: CorMedix Inc.
CPC分类号: A61K9/5123 , A61K9/0019 , A61K9/10 , A61K31/549 , A61P19/02 , A61P31/00
摘要: In one form of the invention, there is provided a method for treating osteoarthritis, the method comprising applying a broad spectrum antimicrobial formulation to the subchondral bone of a mammal. In another form of the invention, there is provided a pharmaceutical composition for treating infections, including infections leading to arthritis.
-
7.
公开(公告)号:US20180185378A1
公开(公告)日:2018-07-05
申请号:US15861248
申请日:2018-01-03
申请人: Cormedix Inc.
发明人: Robert DiLuccio
IPC分类号: A61K31/541 , C07D285/18 , A61K9/20 , A61K9/00 , A61P1/00
CPC分类号: A61K31/549 , A61K9/0031 , A61K9/0053 , A61K9/0065 , A61K9/06 , A61K9/2077 , A61K9/4866 , A61K9/5015 , A61K9/5073 , A61K31/541 , A61P1/00 , C07D285/18
摘要: This invention relates to the prophylactic and/or therapeutic application of antimicrobials that are, for example, administered orally as a delayed release formulation designed to release the drug to the distal small intestine and/or colon in high quantities and density, as a method for the prevention and/or treatment of infections in the colon.
-
公开(公告)号:US20170274223A1
公开(公告)日:2017-09-28
申请号:US15471924
申请日:2017-03-28
申请人: CorMedix Inc.
摘要: Placement of a vascular access device (intravenous, intra-arterial and/or intra-osseous vascular access) in a non-sterile environment greatly increases the risk of infection via the vascular access device. This invention provides an approach for accomplishing sterilization of the site where vascular access will be attempted under non-sterile field conditions. In addition, this invention provides a sterile vascular connector pre-loaded with an antimicrobial, e.g., Taurolidine. Use of the vascular connector provides the antimicrobial concurrently with achieving vascular access, which limits the risk of infection despite access placement under non-sterile field conditions.
-
公开(公告)号:US20220347184A1
公开(公告)日:2022-11-03
申请号:US17675639
申请日:2022-02-18
申请人: CorMedix Inc.
发明人: Bruce Reidenberg , Robert DiLuccio
摘要: A composition comprising: hydrolysable taurolidine; and a hydrolysable lipophilic excipient; wherein the hydrolysable taurolidine is contained within the hydrolysable lipophilic excipient.
-
公开(公告)号:US10517984B2
公开(公告)日:2019-12-31
申请号:US15240447
申请日:2016-08-18
申请人: CorMedix Inc.
发明人: Robert DiLuccio , Z. Paul Lorenc , Randy Milby
IPC分类号: A61L17/00 , A61L17/10 , A61L17/04 , A61B17/06 , A61B17/064
摘要: An antimicrobial suture comprising a filament and taurolidine.
-
-
-
-
-
-
-
-
-